智通财经APP讯，堃博医疗-B(02216)发布公告，于2026年3月21日，买方Broncus China Holding Corporation(公司的全资附属公司)与卖方Max Grand Limited订立股份转让协议，据此，卖方有条件同意出售，而买方有条件同意购买目标股份Valgen Holding Corporation(占目标公司截至本公告日期按全面摊薄及转换基准计算的发行在外股份的3.85%)，总代价为5512.02万美元。
目标集团主要从事提供二尖瓣反流及三尖瓣反流等疾病的系统解决方案。其产品包括二尖瓣修复装置DragonFly™(经股静脉途径)及三尖瓣修复装置DragonFly-TTM。
双方之间的协同效应及潜在合作不仅将提升双方现有产品的竞争力，亦将构建一个涵盖心肺疾病全生命周期的闭环诊疗体系。随着人口老化程度加剧，基于心肺同源的技术协同效应将能为心肺疾病患者提供更高效、精准的诊疗方案，从而为双方开拓更广阔的市场机遇。公司认为，进一步收购事项是让集团更进一步实现心肺疾病整合诊疗的难得机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.